Tofacitinib is an oral, small molecule Janus kinase (JAK) inhibitor that is being
investigated for IBD. In a recent trial of Crohn’s disease (CD) patients (pts), small
treatment effects for tofacitinib vs placebo (PBO) were noted using CD Activity Index
(CDAI)-based enrollment criteria without endoscopic scoring (1). We report post-hoc
analyses of efficacy endpoints (CDAI-based and composite outcomes) in subgroups based
on objective baseline (BL) criteria of disease activity.
To read this article in full you will need to make a payment
Already an online subscriber? Sign in
This article is being published jointly in Gastroenterology and Inflammatory Bowel Diseases.
© 2018 AGA Institute and the Crohn's & Colitis Foundation. Published by Elsevier Inc. All rights reserved.